MAIA Biotechnology, Inc. (MAIA) AI Stock Analysis

• Market Cap: $51.83M
• Dividend Yield: N/A
• Average Volume (3M): 470.24K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.96
• Revenue Growth: N/A
• EPS Growth: 23.55%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -1.11
• Shares Outstanding: 30,307,314
• 10 Day Avg. Volume: 396,207
• 30 Day Avg. Volume: 470,240
• PEG Ratio: -0.09
• Price to Book (P/B): 9.53
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.16
• Enterprise Value/Market Cap: 0.79
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.48
• 1Y Price Target: $14.00
• Price Target Upside: 718.71% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 44 Neutral
• Price Target: ―

MAIA Biotechnology presents a mixed outlook. The company's financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.

MAIA Biotechnology, Inc. Business Overview & Revenue Model

Company Description

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.

How the Company Makes Money

MAIA Biotechnology, Inc. makes money primarily through the development and commercialization of oncology therapies. The company's revenue model includes securing funding through partnerships, licensing agreements, and collaborations with other pharmaceutical companies. These partnerships often involve milestone payments, royalties, and upfront fees linked to the development and eventual commercialization of their drug candidates. Additionally, MAIA may also receive government grants or research funding to support its clinical trials and research activities. As the company progresses its drug candidates through clinical trials and towards regulatory approval, it aims to generate revenue through the successful commercialization of these therapies.

MAIA Biotechnology, Inc. Financial Statement Overview

Summary

MAIA Biotechnology, Inc. is in a development phase with no revenue and significant ongoing expenses leading to negative profitability and cash flows. The balance sheet is strengthened by zero debt, but equity is limited. The financial outlook depends heavily on successful future product development and potential funding opportunities.

Income Statement

MAIA Biotechnology, Inc. shows no revenue generation, typical for early-stage biotech firms focusing on R&D. The company has consistently reported negative EBIT and net income, reflecting the high costs associated with drug development without corresponding revenue. This creates a challenging profitability outlook in the short term.

Balance Sheet

The balance sheet highlights a low debt profile with no outstanding debt, which is positive. However, the stockholders' equity is relatively small, limiting financial flexibility. The company's equity ratio is marginal and has fluctuated over the years, indicating potential volatility in financial stability.

Cash Flow

Operating cash flow has been consistently negative due to ongoing operational expenses without revenue. Free cash flow remains deeply negative, though financing activities have helped maintain liquidity. The cash flow situation reflects a need for external funding to support operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-16.96M	-20.18M	-16.18M	-7.74M	-6.97M
Net Income	-23.25M	-19.77M	-15.81M	-12.50M	-6.64M
Balance Sheet
Total Assets	10.16M	7.57M	12.02M	11.33M	746.50K
Cash, Cash Equivalents and Short-Term Investments	9.60M	7.15M	10.95M	10.57M	663.46K
Total Debt	0.00	0.00	0.00	0.00	463.75K
Total Liabilities	6.52M	7.09M	3.51M	2.15M	2.36M
Stockholders Equity	3.63M	477.51K	8.51M	9.18M	-3.34M
Cash Flow
Free Cash Flow	-15.70M	-13.07M	-11.66M	-4.12M	-1.84M
Operating Cash Flow	-15.70M	-13.07M	-11.66M	-4.12M	-1.84M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	18.18M	9.27M	12.48M	14.03M	798.05K

MAIA Biotechnology, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.71
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MAIA, the sentiment is Negative. The current price of 1.71 is below the 20-day moving average (MA) of 1.79, below the 50-day MA of 1.78, and below the 200-day MA of 1.99, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 45.43 is Neutral, neither overbought nor oversold. The STOCH value of 21.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MAIA.

MAIA Biotechnology, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%
KRON	51 Neutral	$53.65M	―	-59.49%	―	21.15%	46.44%
PDSB	50 Neutral	$55.31M	―	-119.22%	―	―	25.51%
DTIL	50 Neutral	$54.78M	2.40	-50.81%	―	-11.11%	79.74%
GANX	46 Neutral	$58.08M	―	-290.21%	―	-100.00%	44.28%
MAIA	44 Neutral	$51.83M	―	-1131.02%	―	―	23.55%
IMMX	―	$80.84M	―	-111.42%	―	―	―

MAIA Biotechnology, Inc. Corporate Events

MAIA Biotechnology Showcases THIO-101 Trial at ELCC 2025

MAIA Biotechnology, Inc. presented a poster at the European Lung Cancer Congress 2025 on March 28, 2025, showcasing efficacy data from its Phase 2 THIO-101 clinical trial. The trial evaluates THIO in combination with the immune checkpoint inhibitor cemiplimab for patients with advanced non-small cell lung cancer who have not responded to standard therapies. This presentation highlights the company’s ongoing efforts to advance its clinical research and potentially improve treatment options for lung cancer patients.

MAIA Biotechnology Updates Executive Compensation Packages

On February 1, 2025, MAIA Biotechnology, Inc. announced updates to the employment agreements of key executives, including Dr. Vlad Vitoc, Chairman and CEO, and Dr. Sergei Gryaznov, Chief Scientific Officer. These amendments included salary increases and revised bonus structures, enhancing their compensation packages based on performance objectives and corporate goals. The changes reflect a strategic move to retain top leadership talent and align executive incentives with company goals, potentially impacting the company’s operational strategy and competitive positioning in the biotech industry.

MAIA Biotechnology Reports Promising Phase 2 Trial Results

On February 4, 2025, MAIA Biotechnology announced positive updates from its Phase 2 THIO-101 trial for advanced non-small cell lung cancer. The trial showed a significant median overall survival of 16.9 months, suggesting a strong advantage over standard chemotherapy treatments. This development enhances MAIA’s regulatory strategy and could expedite FDA approval, marking a potential breakthrough for patients with limited treatment options.